Skip to main content

Table 8 Robustness Results for Lamivudine

From: A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form

S. No. Parameter As such method Used %RSD for peak area (n = 6) Average retention time Plate count Tailing factor
1 Flow rate (± 0.1 mL/min) 1.0 mL/min 0.9 mL/min 0.2 2.374 9457 1.35
1.0 mL/min 0.7 2.169 7651 1.32
1.1 mL/min 1.0 2.152 9145 1.30
2 Column temperature (± 5 °C) 30 °C 25 °C 0.3 2.134 8640 1.25
30 °C 0.7 2.169 7657 1.31
35 °C 1.5 2.150 9128 1.33
3 Mobile phase composition Buffer:ACN:Methanol, 55:20:30% v/v 55:25:25 0.5 2.136 8648 1.30
55:20:30 0.7 2.169 7653 1.31
55:15:35 0.9 2.164 8475 1.33